Product Highlight - Invokana
- INVOKANA demonstrated statistically significant glycated haemoglobin A1c (HbA1c) reductions and helped more patients achieve the ADA-recommended HbA1c goal of <7%1,4.
- Only Invokana 300 mg demonstrated greater reductions in vs HbA1c sitagliptin 100 mg2.
- INVOKANA results in the excretion of approximately 77 grams to 119 grams of glucose per day3.
- INVOKANA provided greater reductions in body weight and systolic blood pressure vs placebo3.
- INVOKANA showed good tolerability profile with the following most common adverse reactions – female genital mycotic infection, urinary tract infection (UTI) and increased urination3.
1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab.2013;15(4):372-382.
2. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508-2515.
3. Invokana_Approved Prescribing Information_Malaysia_EU SmPC vJan2016.
4: American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016; 39(Supplement 1): S39-S46.
Further information is available in Section 11b, New In This Issue and mims.com
Full prescribing information is available upon request.
MKT-CAN-MY-0026Creation Date: October 2016